<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>RNA-Binding Protein | YuanSilencer</title><link>https://yuansilencer.com/tag/rna-binding-protein/</link><atom:link href="https://yuansilencer.com/tag/rna-binding-protein/index.xml" rel="self" type="application/rss+xml"/><description>RNA-Binding Protein</description><generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Wed, 05 Nov 2025 00:00:00 +0000</lastBuildDate><image><url>https://yuansilencer.com/media/icon_hu_7613a4a452ac7087.png</url><title>RNA-Binding Protein</title><link>https://yuansilencer.com/tag/rna-binding-protein/</link></image><item><title>Identification of RNA-binding protein hnRNP C targeting the 3′UTR of the TAP-associated glycoprotein tapasin in melanoma</title><link>https://yuansilencer.com/publication/2/</link><pubDate>Wed, 05 Nov 2025 00:00:00 +0000</pubDate><guid>https://yuansilencer.com/publication/2/</guid><description>&lt;p>Melanoma cells exploit &lt;strong>hnRNP C&lt;/strong> to bind a repressive site in &lt;strong>tapasin (TAPBP)&lt;/strong> 3′UTR, lowering HLA‑I antigen presentation. Genetic/biochemical disruption of this interaction restores tapasin and boosts HLA‑I surface levels—implicating hnRNP C as a biomarker and target for T‑cell–based immunotherapy.&lt;/p>
&lt;h2 id="abstract-concise-paraphrased">Abstract (concise, paraphrased)&lt;/h2>
&lt;p>The study identifies &lt;strong>hnRNP C&lt;/strong> as an RNA‑binding protein that recognizes a &lt;strong>silencer motif&lt;/strong> within the &lt;strong>TAPBP (tapasin)&lt;/strong> 3′UTR in melanoma.
By binding this site, hnRNP C decreases tapasin expression and limits &lt;strong>HLA class I&lt;/strong> antigen processing and presentation.
Across cell models and patient‑derived materials, loss or inhibition of hnRNP C increases &lt;strong>TAPBP mRNA/protein&lt;/strong> and elevates &lt;strong>HLA‑I&lt;/strong> at the cell surface.
These findings position hnRNP C as a regulator of tumor immune visibility and a potential &lt;strong>therapeutic/diagnostic handle&lt;/strong>.&lt;/p>
&lt;h2 id="key-takeaways">Key takeaways&lt;/h2>
&lt;ul>
&lt;li>&lt;strong>Mechanism&lt;/strong>: hnRNP C engages a &lt;strong>3′UTR silencer&lt;/strong> in &lt;em>TAPBP&lt;/em>, dampening antigen processing and &lt;strong>HLA‑I&lt;/strong> display.&lt;/li>
&lt;li>&lt;strong>Evidence&lt;/strong>: RNA‑protein assays, reporter constructs, perturbation genetics, and analyses of melanoma samples converge on the model.&lt;/li>
&lt;li>&lt;strong>Impact&lt;/strong>: Relieving this repression could enhance &lt;strong>T‑cell recognition&lt;/strong>, offering a route to improve immunotherapy responsiveness.&lt;/li>
&lt;/ul>
&lt;h2 id="suggested-citation">Suggested citation&lt;/h2>
&lt;p>Wang Y, Lazaridou M‑F, Kordaß T, &lt;strong>et al.&lt;/strong> &lt;em>Identification of RNA‑binding protein hnRNP C targeting the 3′UTR of the TAP‑associated glycoprotein tapasin in melanoma.&lt;/em> &lt;strong>OncoImmunology.&lt;/strong> 2024;13(1):2370928. doi:10.1080/2162402X.2024.2370928.&lt;/p></description></item></channel></rss>